A new drug is changing the conversation around obesity in the United States. Back in 2021, the Food and Drug Administration approved a new weight-loss medication, Wegovy in 2021. It has the same active ingredient — semaglutide — as the diabetes drug, Ozempic.
The drugs have become so popular that their manufacturers couldn’t keep up with demand and some pharmacies are still seeing shortages.
Some patients say they’ve vastly improved their lives. There are also critics who worry these drugs are being too widely used for cosmetic weight loss and feeding into an obsession with thinness. And then there’s the question of price and access.
Clearly, it’s a complicated issue! Here to help explain are two doctors: One, an obesity specialist, and another focused on eating disorders.
MPR News Host Cathy Wurzer spoke with Dr. Aaron Kelly, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, and Dr. Mary Bretzman, who specializes in eating disorders with Accanto Health, the parent company of The Emily Program.